Legato Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Legato Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	46,816 +1,466	+3%	+$34.2K	0.1%	296
2026 Q1	$1.07M	Sell	45,350 -678	-1%	-$17.3K	0.1%	274
2025 Q4	$1.34M	Sell	46,028 -10,689	-19%	-$274K	0.12%	283
2025 Q3	$1.07M	Hold	56,717	–	–	0.12%	272
2025 Q2	$795K	Hold	56,717	–	–	0.09%	339
2025 Q1	$887K	Buy	56,717 +13,946	+33%	+$196K	0.12%	280
2024 Q4	$596K	Sell	42,771 -13,437	-24%	-$147K	0.08%	417
2024 Q3	$523K	Hold	56,208	–	–	0.06%	436
2024 Q2	$523K	Buy	+56,208	New	+$508K	0.07%	434

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Legato Capital Management's ARQT Position: Q2 2026 in Review

Legato Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 3.2% in Q2 2026, buying an estimated $34.2K and bringing the position to 46,816 shares worth $1.23M. The position accounts for 0.1% of the portfolio, ranked #296.

Legato Capital Management first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.34M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Legato Capital Management held 46,816 shares of Arcutis Biotherapeutics worth $1.23M as of Q2 2026.
Legato Capital Management bought 1,466 Arcutis Biotherapeutics shares in Q2 2026, an estimated $34.2K.
Arcutis Biotherapeutics made up 0.1% of Legato Capital Management's portfolio in Q2 2026, its #296 holding.
Legato Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
Legato Capital Management's Arcutis Biotherapeutics position peaked at $1.34M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.